TPS468 Background: An unmet medical need remains in patients (pts) with HER2+ gastric or GEJ cancer. HER2 is a validated target in up to 20% of pts with gastric or GEJ cancer. Results of the KEYNOTE-811 trial demonstrated that pembro + trastuzumab and chemo improved progression-free survival (PFS) and overall survival (OS) versus placebo + trastuzumab and chemo for first-line treatment of pts with HER2+ gastric or GEJ cancer with a programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥1 (Janjigian Y et al. N Engl J Med. 2024;391:1360). In the DESTINY-Gastric03 trial, first-line combinations involving T-DXd, a HER2-directed antibody-drug conjugate, and fluoropyrimidine (5-fluorouracil 5-FU or capecitabine CAPE) ± pembro showed acceptable safety and encouraging efficacy in pts with HER2+ gastric or GEJ cancer irrespective of tumor PD-L1 CPS (Janjigian Y et al. Ann Oncol . 2024;35:S878). Building on this evidence, the phase 3 DESTINY-Gastric05 trial aims to evaluate a potentially improved platinum-free treatment approach for all pts with HER2+ gastric or GEJ cancer. Methods: DESTINY-Gastric05 (NCT06731478) is an open-label, randomized, multicenter, phase 3 global trial designed to evaluate the efficacy and safety of T-DXd in combination with 5-FU (or CAPE) + pembro versus standard-of-care chemo with trastuzumab + pembro as first-line treatment in pts with unresectable, locally advanced or metastatic centrally confirmed HER2+ (immunohistochemistry IHC 3+ or IHC 2+/in situ hybridization+) gastric or GEJ cancer with PD-L1 CPS ≥1 (main cohort). Pts must have ≥1 measurable lesion by RECIST v1.1, a left ventricular ejection fraction ≥50%, and an Eastern Cooperative Oncology Group performance status of 0 or 1. In the main cohort, approximately 576 pts will be randomly assigned in a 1:1 ratio to receive: T-DXd 5.4 mg/kg + 5-FU or CAPE + pembro (arm M1); or trastuzumab + platinum-based chemo (either cisplatin + 5-FU or oxaliplatin + CAPE) + pembro (arm M2). The primary efficacy endpoint is PFS based on blinded independent central review (BICR), and the key secondary endpoint is OS. Other secondary endpoints include overall response rate, duration of response, and time to response per RECIST v1.1 assessed by BICR and investigator. Safety and tolerability will also be assessed. A separate exploratory cohort (approximately 150 pts) will evaluate the efficacy and safety of T-DXd in combination with 5-FU or CAPE versus trastuzumab plus standard-of-care chemo in pts with PD-L1 CPS <1. Recruitment started on February 27, 2025; as of August 6, 2025, 17 of a planned 726 pts had been enrolled. Clinical trial information: NCT06731478 .
Shitara et al. (2026) studied this question.